Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis

被引:7
|
作者
Poonam, Jain P. [1 ]
Mayur, Parihar [3 ]
Rayaz, Ahmed [2 ]
Aby, Abraham [2 ]
Auro, Vishwabandya [2 ]
Biju, George [2 ]
Vikram, Mathews [2 ]
Alok, Srivastava [2 ]
Vivi, Srivastava M. [1 ]
机构
[1] Christian Med Coll & Hosp, Cytogenet Unit, Vellore 632004, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Hematol, Vellore 632004, Tamil Nadu, India
[3] Tata Med Ctr, Dept Cytogenet, Kolkata, W Bengal, India
关键词
Chronic myelogenous leukemia; BCR/ABL1; fusion; atypical FISH signals; CHRONIC-MYELOID-LEUKEMIA; D-FISH PATTERNS; DERIVATIVE CHROMOSOME-9; VARIANT TRANSLOCATIONS; CYTOGENETIC RESPONSE; GENE REARRANGEMENTS; PERIPHERAL-BLOOD; CLONAL EVOLUTION; CML; DELETIONS;
D O I
10.4103/0377-4929.101742
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Chronic myelogenous leukemia (CML) is characterised by the t(9;22)(q34;q11.2) which results in the formation of the BCR/ABL1 fusion gene. Occasionally, the t(9;22) may be associated with submicroscopic deletions of chromosomes 9 and/or 22 which appear to be associated with a worse prognosis. Three or four-way variant t(9;22) may also occur. All these changes as well as gain of the Philadelphia chromosome which represents disease progression can be detected by fluorescence in situ hybridization (FISH) analysis. FISH analysis at presentation is used to determine the number of cells with BCR/ABL1 fusion and establish whether the patterns are typical or atypical. Response to therapy can then be monitored by serial testing. Patients and Methods: The study group consisted of all patients diagnosed or suspected to have CML who had interphase FISH analysis at presentation on peripheral blood/bone marrow using a commercially available BCR/ABL1 dual colour, dual fusion probe. The study was performed at a tertiary hospital in India between 2004 and 2010. Results: There were 1076 diagnostic samples which were positive for BCR/ABL1 fusion. Typical dual fusion signals (two fusions, one red and one green, 2F1R1G) were seen in 801 cases (74 %). Atypical signal patterns were seen in 275 cases (26%). These were: 1F1R2G (4%), 1F2R1G (2.5%) and 1F1R1G (11%) representing deletions of the derivative 9 involving chromosome 9 sequences, chromosome 22 sequences, or both respectively; 3F1R1G (6.5%) usually representing gain of an additional Philadelphia chromosome and 1F2R2G (1%) representing a three-or four-way variant translocation. More than one signal pattern was seen in 1%. Conclusions: Our findings were similar to the literature with respect to the distribution of signal patterns except that we had a lower number of patients with variant translocations. While each signal pattern is typically associated with a particular abnormality, there can be more than one explanation for each pattern. Hence, metaphase FISH analysis is the "gold standard" for the interpretation of signal patterns.
引用
下载
收藏
页码:347 / 351
页数:5
相关论文
共 50 条
  • [21] Variant Isoforms of BCR-ABL1 in Chronic Myelogenous Leukemia Reflect Alternative Splicing of ABL1 in Normal Tissue - Letter
    Khorashad, Jamshid S.
    Milojkovic, Dragana
    Reid, Alistair G.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (07) : 2152 - 2152
  • [22] Detection of BCR/ABL fusion product in normoblasts in a case of chronic myelogenous leukemia
    McFarlane, R
    Sun, T
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (09) : 1240 - 1244
  • [23] Fluorescence in situ hybridization characterization of different cryptic BCR-ABL rearrangements in chronic myeloid leukemia
    Haigh, S
    Cuthbert, G
    CANCER GENETICS AND CYTOGENETICS, 2004, 155 (02) : 132 - 137
  • [24] Monitoring the course of chronic myelogenous leukemia by fluorescence in situ hybridization
    Seong, CM
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 2) : 53 - 57
  • [25] Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
    Dewald, GW
    Wyatt, WA
    Juneau, AL
    Carlson, RO
    Zinsmeister, AR
    Jalal, SM
    Spurbeck, JL
    Silver, RT
    BLOOD, 1998, 91 (09) : 3357 - 3365
  • [26] Comparison Of BCR-ABL1/ABL1 and BCR-ABL1/GUS Ratios At Different Clinical Decision Cut-Offs In Chronic Phase Chronic Myelogenous Leukemia Patients On Imatinib
    Huet, Sarah
    Souche, Denis
    Magaud, Jean-Pierre
    Cony-Makhoul, Pascale
    Guillermin, Yann
    Heiblig, Mael
    Michallet, Mauricette
    Nicolini, Franck E.
    Hayette, Sandrine
    BLOOD, 2013, 122 (21)
  • [27] Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more
    Cea, M.
    Cagnetta, A.
    Garuti, A.
    Cirmena, G.
    Rocco, I.
    Moran, E.
    Grillo, V.
    Ballestrero, A.
    Patrone, F.
    Nencioni, A.
    JOURNAL OF BUON, 2009, 14 (04): : 565 - 573
  • [28] Eosinophils and basophils carry the fused bcr/abl gene in chronic myelogenous leukemia: Direct fluorescence in situ hybridization (FISH) analysis on the blood smears.
    Lee, W
    Kim, Y
    Lee, Y
    Han, KJ
    Hong, DS
    BLOOD, 1997, 90 (10) : 3712 - 3712
  • [29] THE BCR-ABL GENE IN CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    CANCER SURVEYS, 1992, 15 : 37 - 51
  • [30] DETECTION OF BCR-ABL FUSION IN CHRONIC MYELOGENEOUS LEUKEMIA BY INSITU HYBRIDIZATION
    TKACHUK, DC
    WESTBROOK, CA
    ANDREEFF, M
    DONLON, TA
    CLEARY, ML
    SURYANARAYAN, K
    HOMGE, M
    REDNER, A
    GRAY, J
    PINKEL, D
    SCIENCE, 1990, 250 (4980) : 559 - 562